Derek Maetzold founded Castle Biosciences in 2007 and initiated operations in late 2008 with co-founders Toby Juvenal and Kristen Oelschlager. He is currently President, CEO and a board member of Castle Biosciences. Mr. Maetzold founded Castle Biosciences with the belief that the traditional approach to developing a treatment plan for certain cancers using clinical and pathology factors alone can be improved by incorporating personalized genomic information. Castle Biosciences represents Mr. Maetzold’s first experience in molecular diagnostics. His prior 24 years was spent in pharmaceutical development and commercialization – roughly splitting time between two multinational pharmaceutical firms and two emerging biotechnology companies. Mr. Maetzold’s career in pharmaceuticals was primarily focused on new product development through business development and commercial oversight of pre-approved therapies. Mr. Maetzold currently serves as a director of PreludeDx™, the Coalition for 21st Century Medicine (C21) and IMPACT Melanoma. He is also a co-author on numerous publications as well as a co-inventor of multiple technologies. Mr. Maetzold was named by Ernst & Young LLP (EY) as an Entrepreneur Of The Year® 2024 Gulf South Award winner.